Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes

• Published in: Therapeutic advances in neurological disorders Vol. 18; p. 17562864251319656
• Main Authors: Jin, Lei, Zou, Zhangyu, Wang, Qinzhou, Zeng, Wenshuang, Jiang, Qilong, Chen, Jing, Shi, Jianquan, Yu, Yanyan, Hong, Daojun, Zeng, Quantao, Tan, Song, Yue, Yaoxian, Zhang, Zhouao, Zhang, Yong, Guo, Xiuming, Du, Lei, Zhao, Zhongyan, Huang, Shixiong, Chen, Ying, Wu, Zongtai, Yan, Chong, Xi, Jianying, Song, Jie, Luo, Sushan, Zhao, Chongbo
• Format: Journal Article
• Language: English
• Published: England SAGE Publications 01.01.2025; SAGE Publishing
• Subjects: Original Research; early-onset; thymoma; late-onset; efgartigimod; therapeutic response; generalized myasthenia gravis
• ISSN: 1756-2864; 1756-2856; 1756-2864
• DOI: 10.1177/17562864251319656

Plain language summary Patterns and predictors of therapeutic response to efgartigimod in AChR generalized myasthenia gravis Myasthenia Gravis (MG) is an autoimmune disorder that can lead to potentially life-threatening complications. Efgartigimod is an approved biologic for generalized myasthenia gravis (gMG). However, the patterns and predictors of therapeutic response to efgartigimod among the acetylcholine receptor-generalized MG (AChR-gMG) subtypes remain inconclusive. Our findings revealed patterns of treatment responses among AChR-gMG subtypes, with LOMG patients potentially presenting a more sustained response.